

| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Please complete application in full, sign and date, then fax to: 877-427-7290

Or email to: ViatrisPAP@viatris.com

- The PAP Application must be complete to be reviewed for patient program eligibility. Please ensure all areas of the form are completed in full, including all signatures.
- To be considered for the Viatris Patient Assistance Program, all applicants must satisfy the following requirements and eligibility criteria:
 - o Applicants qualify for the program financial requirements.
 - Applicants must be a current United States resident (includes U.S Territories).
 - Applicant must be fully uninsured or if insured, have no prescription drug insurance.
 - The requested product must be prescribed by a licensed U.S. healthcare professional for a Food and Drug Administration (FDA) approved indication.
- Each applicant will be individually assessed for program eligibility based on the information provided within this application.
- Applicants will only be evaluated for eligibility upon receipt of a completed and signed Viatris Patient Assistance Program (PAP) Application.







| Patient Information | | | | |
|------------------------------------|---------------------------|---------------------|--------------------------|-------------------|
| Name: | | City: | State: | ZIP: |
| | | | | |
| Preferred Contact: Cell Phone Home | | | | <u></u> - |
| Insurance: Uninsured Commerc | al Government Oth | ner | Rx Coverage: Yes | □ No |
| Insurance Name: | Insurance ID Number: | | *No | PO Boxes Accepted |
| | | | | |
| Prescriber Information | | | | |
| | | | | |
| Prescriber Name: | | | Prescriber NPI: | |
| Facility Name: | | | State License #: | |
| Facility Address: | | City: | State: | ZIP: |
| Primary Office Contact: | | | Fax Number: | |
| Phone Number: | Office Contact Email: | | | |
| | | | | |
| Prescriber Shipping Address (| Only complete if shipping | address is differei | nt than address listed a | above) |
| Prescriber Name: | | | Facility Name: | |
| Shipping Address: | | City: | State: | ZIP: |
| Shipment Contact Name: | | | | |
| Phone Number: | Contact Email: | | | |



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Ohio Prescriber Mandatory Subsection (Select an option below, complete the related fields, then sign & date)

MANDATORY SUBSECTION FOR ALL OHIO HCPs

| a Terminal license allo information www.pharn | Distributor of Dangerous Drugs ("TDDD") or lows a business entity to receive, purchase, a non TDDD licensing requirements for prescri | Company, may only provide prescription drugs to a prescriber whose practice is licensed as is exempt from such licensure under Ohio Revised Code ("ORC") § 4729.541. A TDDD nd possess prescription drugs, including drug samples, for distribution to patients. For more ibers, please visit the Ohio Board of Pharmacy website at to f exemptions, please refer to section 4729.541 of the ORC. The above information is nor should it be construed, as legal advice. | | | |
|--|---|---|--|--|--|
| Please select and complete one of the following and sign below: | | | | | |
| | The practice at which I work, | , located at the address I provided above, has an active TDDD license that | | | |
| | allows me to receive and store the requested prescription drug products at this location. The TDDD license number is which expires on | | | | |
| -OR- | | | | | |
| | The practice at which I work,licensing exemptions in ORC § 4729.541. | , located at the address I provided above, is subject to one of the TDDD | | | |
| By signing below, I warrant that the information provided above is complete and accurate and attest that I can receive and store the requested prescription drug products at the address I provided because I hold an unrestricted, active TDDD license or my practice is exempt from obtaining a TDDD license under ORC § 4729.541. | | | | | |
| Prescriber | Signature: | Date: | | | |
| (Original signature -and- date required, stamped signatures not accepted) | | | | | |



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8am to 5pm EST |



| Arixtra® (fondaparinux sodium) injection, |
|---|
| solution |
| 2.5mg/0.5mL PFS 10PK |
| QTY |
| |
| 5mg/0.4mL PFS 10PK |
| QTY |
| 7.5mg/0.6mL PFS 10PK |
| QTY |
| 4.0mg/0.0ml DEC 4.0DV |
| 10mg/0.8mL PFS 10PK |
| QTY |
| Cortifoam® (hydrocortisone acetate 10%) |
| rectal foam |
| 10% 15g |
| QTY |
| Cystagon® (Cysteamine bitartrate) |
| capsules |
| 50mg C 500s |
| QTY |
| 450 0 500- |
| 150mg C 500s |
| QTY |
| Denavir® (penciclovir) Cream |
| 1% 5gm |
| QTY |
| Dipentum ® (olsalazine sodium) capsule |
| |
| 250mg C 100s |
| QTY |
| Dymista® azelastine hydrochloride & |
| fluticas one propionate) nas al spray |
| 137/50mcg Nasal Spray 23g |
| QTY |
| EM SAM® Transdermal System |
| 12 mg/24 hr Bx30 |
| QTY |
| |
| 6 mg/24 hr Bx 30 |
| QTY |
| TDS 9 mg/24 hr Bx30 |
| OTY TEO 3 Hg/24 HI EXOU |
| |
| ERM EZA™ (levothyroxine sodium) oral |
| solution |
| 150 mcg/5mL) 150mL |
| QTY |
| 150 mcg/5mL) 75mL |
| QTY |
| |

| Evoclin® (clindamycin phosphate) Foam, |
|---|
| 1% 1% 100gm |
| |
| QTY |
| 1% 50gm |
| QTY |
| Falls at a leg (falls amounts) |
| Felbatol® (felbamate) |
| 400mg T 100s |
| QTY |
| 600mg T 100s |
| QTY |
| Q11 |
| 600mg OS 8oz |
| QTY |
| 600mg OS 32oz |
| QTY |
| |
| Gastrocrom® (cromolyn sodium, USP) oral |
| concentrate |
| 100mg 5mL Oral Concentrate 96s |
| QTY |
| Im peklo® (clobetasol propionate) |
| Lotion MDP 0.05% |
| QTY |
| QI I |
| Luxiq® (betamethas onevalerate) Foam |
| 0.12% 100gm |
| QTY |
| 0.40% 505 |
| 0.12% 50gm |
| QTY |
| Miacalcin® Injection |
| 200 IU/mL 2mL MDV 1pk |
| OTY |
| QZ I I |
| Muse® (alprostadil) urethral |
| 250mcg Suppository 6s |
| Looning Cappository of |
| QTY 230ming cuppository 63 |
| QTY |
| TOTY 500mcg Suppository 6s |
| QTY |
| TOTY 500mcg Suppository 6s |
| 500mcg Suppository 6s |
| 500mcg Suppository 6s TOTY 1000mcg Suppository 6s |
| 500mcg Suppository 6s TOTY 1000mcg Suppository 6s |
| TY 500mcg Suppository 6s TY 1000mcg Suppository 6s TY Olux® (clobetas of propionate) Foam, 0.05% |
| TY 500mcg Suppository 6s TY 1000mcg Suppository 6s TY Olux® (clobetas of propionate) Foam, 0.05% 0.05% 50gm |
| TY 500mcg Suppository 6s TY 1000mcg Suppository 6s TY Olux® (clobetas of propionate) Foam, 0.05% |
| TY 500mcg Suppository 6s TY 1000mcg Suppository 6s TY Olux® (clobetas of propionate) Foam, 0.05% 0.05% 50gm |
| TY 500mcg Suppository 6s TY 1000mcg Suppository 6s TY Olux® (clobetas of propionate) Foam, 0.05% 0.05% 50gm |

| Da wie wa wa is 40 (formatoral fumorata) |
|--|
| Perforomist® (formoterol fumarate) Inhalation Solution |
| |
| 20 mcg / 2 mL 30x1 |
| QTY |
| 00 /0 / 00 / |
| 20 mcg / 2 mL 60x1 |
| QTY |
| |
| Pretomanid Tablets |
| 200mg T 26 |
| |
| QTY |
| Proctofoam ® HC (hydrocortisone acetate |
| 1% and pramox ine hydrochloride 1%) |
| HC 1% 10g |
| |
| QTY |
| ROWA SA® (mes alamine) Rectal |
| Suspension |
| 60mL Rectal Susp 7s |
| · · |
| QTY |
| 60mL Rectal Susp 28s |
| |
| QTY |
| sfROWA SA® (mesalamine) Rectal |
| Suspension |
| 60mL Rectal Susp 7s |
| QTY |
| QIY |
| 60mL Rectal Susp 28s |
| QTY |
| QIT |
| Wixela Inhub® (fluticasone propionate and |
| s almeterol inhalation pow der, USP) |
| 100mcg/50mcg 60/lnh |
| OTY |
| GET I |
| 250mcg/50mcg 60/lnh |
| QTY |
| |
| 500mcg/50mcg 60/lnh |
| QTY |
| |
| XULANE® (norelgestromin and ethinyl |
| estradiol transdermal system) |
| TDS 0.15mg/0.035mg/QD 3s |
| QTY |
| |
| Yupelri® (revefenacin) inhalation solution |
| - apolitic (rotorollasiii) lililalation solution |
| 175mcg / 3mL 30s |
| QTY |
| |



Viatris Patient Assistance Program Application | Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST



| Prescription Details- Please complete a | all relevant prescription details below | |
|---|---|--|
| Patient Name: | Patient | DOB: |
| Prescriber Name: | | Prescriber NPI: |
| Day Supply: | | |
| Directions: | | |
| _ | | |
| Prescriber Certification and Prescription | on Signature | |
| product I have prescribed to the applicant within I Administration (FDA) approved indication, and that I is no longer medically necessary for this patient's tree | Assistance Program Application is complete and accurate this application is based on my professional judgmen will supervise the patient's medical treatment. I will notificat the patient I have obtained from my patient all information to Viatris and their agents and representation. | t of medical necessity for a Food and Drug y Viatris PAP immediately if the Viatris product required written authorizations for the release |
| and representatives to verify my patient's insurance | s and its agents and representatives is for the sole use e coverage status, to assess the patient's eligibility for ise administer the product and related services. I unders | participation in the Viatris Patient Assistance |
| patient may no longer be eligible for the Program, patient's financial and/or insurance status. I agree the mail and/or telephone. I understand that I am under respectively. | program at any time. I understand that if my patient's fand I agree to immediately notify a Viatris PAP repres hat Viatris PAP may contact me for additional information obligation to prescribe any Viatris product and that I hiscribing a Viatris product. I agree that I will not sell, sprovided by the Program. | entative if I become aware of changes in the on relating to this application either by fax, e- ave not received, nor will I receive, any benefit |
| using the Surescripts network. Surescripts requires | application and enrollment process, United BioSource C that Prescriber agree to comply with all Surescripts' to cable laws, and use of data. All Surescripts disclaiment | erms and conditions, including confidentiality, |
| of Viatris to use and disclose as necessary for verific | ion, I authorize the release of medical and/or other patie cation of patient eligibility, and to furnish any information and that Program duration per eligibility period is 12 mo | on this form to the insurer of the applicant for |
| Prescriber Certification & Prescription Signature: | (original signature required) | Date: |



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Patient Authorization and Agreement Signature

By signing this Authorization, I authorize each of my physicians, pharmacists, including any non-commercial pharmacy that receives my prescription ("my Prescribed Product"), and other healthcare providers (together "Healthcare Providers") and each of my health insurers, if any (together, "Insurers") to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, "Protected Health Information") to Viatris, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, "Viatris") including providers of alternate sources of funding for prescription drug costs, and other service providers supporting the Viatris Patient Assistance Program (PAP) (collectively, the "Program") for the purposes described below.

Specifically, I authorize disclosure of my Protected Health Information in order to:

- I. Enroll me in, and contact me about the Program, including online support, financial assistance services, and co-pay assistance services, as applicable,
- II. Communicate with my Healthcare Providers and Insurers about benefits, coverage, and medical care, including compliance with Product treatments,
- III. Facilitate dispensing of my prescription by a non-commercial pharmacy,
- IV. Provide me with educational materials, information and services related to my treatment experience with my prescribed medication and my condition,
- V. Verify, investigate, and coordinate with my Insurers regarding my prescribed medication, and
- VI. Contact me as otherwise required or permitted by law.

Once my Protected Health Information has been disclosed to Viatris, I understand that federal privacy laws no longer protect the information. However, Viatris agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this Authorization or as permitted by law. I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Viatris Patient Assistance Program and the services provided by Viatris under the Program. If I refuse to sign the Authorization, or revoke my Authorization later, I understand that this means I will not be able to participate in or receive assistance from the Program.

I understand that my signed Authorization is valid for 5 years from the date of my signature, and that I may revoke this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the Authorization. I understand that to revoke this Authorization I may mail a request to 5005 Greenbag Road Morgantown, WV 26508, fax to 877-427-7290, or by calling 888-417-5780. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

I understand that if I qualify and I am enrolled in the Program sponsored by Viatris, I will receive my Prescribed Product from Viatris only pursuant to a legally valid prescription from my health care provider. I understand that if I qualify and I am enrolled in the Program, Viatris will provide me my Prescribed Product free of charge for the duration of the enrollment period so long as I have a legally valid prescription for my Prescribed Product. I understand that I am not required to continue treatment with my Prescribed Product if I gain insurance coverage, or to receive treatment from any given provider. I understand and agree that I must notify Viatris PAP at 888-417-5780 immediately if my insurance status changes during the Program enrollment period. I understand and agree that neither I nor my Insurers, if applicable, will be charged for the supply of my Prescribed Product that I received from the Program, and that under NO circumstances may I claim reimbursement from my Insurers or any other third party for the Prescribed Product provided to me free of charge from the Program. I understand that Viatris reserves the right at any time without notice to modify or discontinue the Program and its criteria.

I understand that I am providing 'written instructions' to Viatris under the Fair Credit Reporting Act authorizing Experian on behalf of Viatris to obtain information from my credit profile or other information from Experian. I authorize Viatris and its service providers to obtain such information solely for the purpose of determining financial qualifications for the Program. I understand that I must affirmatively agree to the terms in this notice by signing below in order to proceed in the Program financial screening process.

5

My signature certifies that I have read and understand the above statements and agree to the outlined terms.

| Patient Name (Print): | Patient Signature: | | Date: |
|---|----------------------------------|---------------------------------------|------------------------|
| | | | |
| Patient Authorized Representativ | е | | |
| permit Viatris PAP Support Services represe my application, insurance and financial quest ssues. I may cancel this Patient Authorized F | tions, any missing documentation | n and other issues related to my enro | |
| Name of Authorized Representative: | | Relationship to Patient: | |
| Felephone Number: | Email: | | |
| By signing below, I, the patient, allow this rep | resentative to speak on my beha | If on any matter regarding my enrollm | nent with the Program. |
| Patient Signature: | | | Date: |

